These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. Kirla R; Salminen E; Huhtala S; Nuutinen J; Talve L; Haapasalo H; Kalimo H J Neurooncol; 2000; 46(1):71-80. PubMed ID: 10896207 [TBL] [Abstract][Full Text] [Related]
8. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Hilton DA; Love S; Barber R; Ellison D; Sandeman DR Neurosurgery; 1998 Apr; 42(4):724-9. PubMed ID: 9574635 [TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. Yang P; Hirose T; Hasegawa T; Seki K; Sano T; Hizawa K Cancer; 1995 Aug; 76(4):618-25. PubMed ID: 8625155 [TBL] [Abstract][Full Text] [Related]
10. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. Heesters MA; Koudstaal J; Go KG; Molenaar WM J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205 [TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas. Hagel C; Krog B; Laas R; Stavrou DK J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174 [TBL] [Abstract][Full Text] [Related]
12. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Gorczyca W; Markiewski M; Kram A; Tuziak T; Domagala W Virchows Arch; 1995; 426(3):229-33. PubMed ID: 7773501 [TBL] [Abstract][Full Text] [Related]
14. Expression of the p53 protein in a spectrum of astrocytic tumours. Ellison DW; Gatter KC; Steart PV; Lane DP; Weller RO J Pathol; 1992 Dec; 168(4):383-6. PubMed ID: 1336544 [TBL] [Abstract][Full Text] [Related]
15. [Measurement of PCNA labeling index in astrocytic tumors]. Beppu T; Arai H; Kanaya H; Sasaki K No Shinkei Geka; 1992 Dec; 20(12):1255-9. PubMed ID: 1362456 [TBL] [Abstract][Full Text] [Related]
16. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
17. p53 protein overexpression in astrocytic neoplasms. Cho MY; Jung SH; Kim TS Yonsei Med J; 1995 Dec; 36(6):521-6. PubMed ID: 8599254 [TBL] [Abstract][Full Text] [Related]